A recent finding is related to the agonists of FXR, such as obeticholic acid used in some trials for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), where itching was reported in a third of patients. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.